FDA Opens Oncology Website

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 9
Volume 9
Issue 9

ROCKVILLE, Md-The Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) has opened a new “Oncology Tools” website. It provides specialized information for health professionals, and allows patients and other consumers to access such information as cancer drug labels, approval summations, and Oncologic Drugs Advisory Committee (ODAC) meeting transcripts. The website may be found at http://www.fda.gov/cder/cancer.

ROCKVILLE, Md—The Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) has opened a new “Oncology Tools” website. It provides specialized information for health professionals, and allows patients and other consumers to access such information as cancer drug labels, approval summations, and Oncologic Drugs Advisory Committee (ODAC) meeting transcripts. The website may be found at http://www.fda.gov/cder/cancer.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.